Study the Effect of Olibanum (Boswellia Carterii) on Hyperuricemia in Rat’s Module


  • khairullah mohammed Department of Clinical Laboratory Sciences, College of Pharmacy, University of Basrah, Basrah, Iraq
  • Basim J. Hameed Department of Clinical Laboratory Sciences, College of Pharmacy, University of Basrah, Basrah, Iraq
  • Nadheerah Neamah Department of Pharmacology and Toxicology, College of Pharmacy, University of Basrah, Basrah, Iraq



Olibanum; Uric acid; Renal function; Liver function; Xanthine oxidase


A current investigation aimed to assess the antihyperuricemic activity of the Boswellia Carterii plant and investigate the action of urate-lowering effect in a rat pattern of hyperuricemia generated by potassium-oxonate. Rats used in the research were randomized into five groups (n=6). The rats in the negative group, allopurinol group, olibanum 50 mg/kg group, and olibanum 100 mg/kg group received intraperitoneal injections of potassium oxonate (PO) twice a week at a dose of 250 mg/kg. The normal control group was supplied food and drink without any intervention. As a positive one control group, the olibanum 50 mg/kg group received daily oral administration of 50 mg/kg of olibanum powder dissolved in 0.5 L of distal water, and the positive two olibanum 100mg/kg group treated with 100mg/kg of olibanum powder dispersed in 0.5L of distal water orally each day. Allopurinol (5mg/kg) was administered orally to rats in the allopurinol group daily. Each group's animals were slaughtered, blood was taken, and serum was isolated for uric acid (UA) laboratory analysis and other biochemical parameters. Uric acid (UUA) and creatinine (UCr) in urine were also measured. The investigation results demonstrated a significantly substantial reduction in blood UA and modest inhibition of xanthine oxide (XOD) in rats with hyperuricemia that were given olibanum solution. Compared to the hyperuricemic control group, all groups showed non-significant variations in the kidney (Urea and CreaC) and liver (ALT, AlkP, and AST) functioning.


Han B, Gong M, Li Z, Qiu Y, Zou Z. NMR-Based Metabonomic Study Reveals Intervention Effects of Polydatin on Potassium Oxonate-Induced Hyperuricemia in Rats. Oxid Med Cell Longev. 2020;2020.

Zhao Z an, Jiang Y, Chen Y yu, Wu T, Lan Q sheng, Li Y mei, et al. CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia. Acta Pharmacol Sin. 2022;43(1):121–32.

Wu J, Zhang YP, Qu Y, Jie LG, Deng JX, Yu QH. Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients. Int J Rheum Dis. 2019;22(8):1445–51.

Hou YL, Yang XL, Wang CX, Zhi LX, Yang MJ, You CG. Hypertriglyceridemia and hyperuricemia: A retrospective study of urban residents. Lipids Health Dis. 2019;18(1):11–5.

Wang YY, Chi J, Che K, Chen Y, Sun X, Wang YY, et al. Fasting plasma glucose and serum uric acid levels in a general Chinese population with normal glucose tolerance: A U-shaped curve. PLoS One [Internet]. 2017;12(6):1–11. Available from:

Katayama A, Yokokawa H, Fukuda H, Ono Y, Isonuma H, Hisaoka T, et al. Achievement of target serum uric acid levels and factors associated with therapeutic failure among japanese men treated for hyperuricemia/gout. Intern Med. 2019;58(9):1225–31.

Tian S, Liu Y, Feng A, Zhang S, Caprio M, Conte C, et al. Sex-Specific Differences in the Association of Metabolically Healthy Obesity With Hyperuricemia and a Network Perspective in Analyzing Factors Related to Hyperuricemia) Sex-Specific Differences in the Association of Metabolically Healthy Obesity With Hyperuricemia and a Network Perspective in Analyzing. Article [Internet]. 2020;11:1. Available from:

Winder M, Owczarek AJ, Mossakowska M, Broczek K, Grodzicki T, Wierucki Ł, et al. Prevalence of hyperuricemia and the use of allopurinol in older poles-results from a population-based polsenior study. Int J Environ Res Public Health. 2021;18(2):1–14.

O’Dell JR, Brophy MT, Pillinger MH, Neogi T, Palevsky PM, Wu H, et al. Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management. NEJM Evid. 2022;1(3):1–11.

Ragab G, Elshahaly M, Bardin T. Gout: An old disease in new perspective – A review. J Adv Res [Internet]. 2017;8(5):495–511. Available from: http://dx.doi. org/10.1016/ j.jare. 2017. 04.008

Alamdar A, Syed S, Fahira A, Yang Q, Chen J, Li Z, et al. The Relationship between Alcohol Consumption and Gout : A Mendelian Randomization Study. 2022;

Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014;26(2):186–91.

Bove M, Cicero AFG, Veronesi M, Borghi C. An evidence-based review on urate-lowering treatments: Implications for optimal treatment of chronic hyperuricemia. Vasc Health Risk Manag. 2017;13:23–8.

Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet. 2007;46(8):623–44.

Cicero AFG, Fogacci F, Kuwabara M, Borghi C. Therapeutic strategies for the treatment of chronic hyperuricemia: An evidence-based update. Med. 2021;57(1):1–18.

Tátrai P, Erdő F, Dörnyei G, Krajcsi P. Modulation of urate transport by drugs. Pharmaceutics. 2021;13(6):1–22.

Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K, Sonoyama K, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens. 2008;21(10):1157–62.

Benn CL, Dua P, Gurrell R, Loudon P, Pike A, Ian Storer R, et al. Physiology of hyperuricemia and urate-lowering treatments. Front Med. 2018;5(MAY):1–28.

Al-Yasiry ARM, Kiczorowska B. Frankincense - Therapeutic properties. Postepy Hig Med Dosw. 2016;70:380–91.

Mahdian D, Abbaszadeh-Goudarzi K, Raoofi A, Dadashizadeh G, Abroudi M, Zarepour E, et al. Effect of Boswellia species on the metabolic syndrome: A review. Iran J Basic Med Sci. 2020;23(11):1374–81.

Almjalawi SA, Sh AM. Antibacterial Activity of Boswellia carterii Aqueous Extract and Its Effect on Phagocytosis in vitro. 2022;77(2):545–52.

Feng Y, Zhang Q, Sun L. Five terpenoids from the gum resin of Boswellia carterii and their cytotoxicity. Fitoterapia [Internet]. 2021;154(July):105017. Available from:

Huang K, Chen Y, Liang K, Xu X, Jiang J, Liu M, et al. Review of the Chemical Composition, Pharmacological Effects, Pharmacokinetics, and Quality Control of Boswellia carterii. Evidence-based Complement Altern Med. 2022;2022.

Sun X, Geng Y, Wang X, Qin D, Yu J. Cembrane-type diterpenoids from the gum resin of Boswellia carterii and their biological activities. RSC Adv. 2019;10(2):746–55.

Chevrier MR, Ryan AE, Lee DYW, Zhongze M, Wu-Yan Z, Via CS. Boswellia carterii extract inhibits TH1 cytokines and promotes TH2 cytokines in vitro. Clin Diagn Lab Immunol. 2005;12(5):575–80.

Patil JS. Pharmaceutical and medicinal applications of Olibanum gum and its constituents : A review Available online through Pharmaceutical and medicinal applications of Olibanum gum and its constituents : A review. 2015;(August):1–4.

Zaki AA, Hashish NE, Amer MA, Lahloub MF. Cardioprotective and antioxidant effects of oleogum resin “Olibanum” from Bos Boswellia carteri Birdw. (Bursearceae). Chin J Nat Med [Internet]. 2014;12(5):345–50. Available from:

Mohamed DA, Al-okbi SY. Evaluation of anti-gout activity of some plant food extracts. Pol J Food Nutr Sci. 2008;58(3):389–95.

Marefati N, Beheshti F, Mokhtari-Zaer A, Shafei MN, Salmani H, Sadeghnia HR, et al. The effects of Olibanum on oxidative stress indicators, cytokines, brain derived neurotrophic factor and memory in lipopolysaccharide challenged rats. Toxin Rev [Internet]. 2020;0(0):1–14. Available from:

Bilal M, Ahmad S, Rehman T, Ghauri AO, Khalid S, Abbasi WM, et al. Anti-Hyperuricemic and Uricosuric Potential of Berberis vulgaris in Oxonate-Induced Hyperuricemic Rats. Dose-Response. 2021;19(3):1–6.

Qi X, Chen H, Guan K, Wang R, Ma Y. Anti-hyperuricemic and nephroprotective effects of whey protein hydrolysate in potassium oxonate induced hyperuricemic rats. J Sci Food Agric. 2021;101(12):4916–24.

Hameed BJ, Ramadhan UH. Xanthine oxidase inhibitory, antihyperuricemic, anti-inflammatory, antinociceptive activity of α-lipoic acid in gouty arthritis model. Asian J Pharm Clin Res. 2018;11(12):483–7.

Maiuolo J, Oppedisano F, Gratteri S, Muscoli C, Mollace V. Regulation of uric acid metabolism and excretion. Int J Cardiol [Internet]. 2016;213:8–14. Available from:

Hameed BJ, Abood HS, Ramadhan UH. Gout Model. 2018;2018(3):695–9.

Chen M, Ye C, Zhu J, Zhang P, Jiang Y, Lu X, et al. Bergenin as a Novel Urate-Lowering Therapeutic Strategy for Hyperuricemia. Front Cell Dev Biol. 2020 Jul 29;8.

O’Dell JR, Brophy MT, Pillinger MH, Neogi T, Palevsky PM, Wu H, et al. Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management. NEJM Evid [Internet]. 2022;1(3):1–11. Available from: https://evidence.

Azadmehr A, Ziaee A, Ghanei L, Huseini HF, Hajiaghaee R, Tavakoli-Far B, et al. A randomized clinical trial study: Anti-oxidant, anti-hyperglycemic and anti-hyperlipidemic effects of olibanum gum in type 2 diabetic patients. Iran J Pharm Res. 2014;13(3):1003–10.

Wulandari A, Dirgahayu P, Wiboworini B. Anti-hyperurisemic Activity of Combination of Beetroot Powder (Beta vulgaris L.) And Allopurinol in Potassium Oxonate-Induced White Rats. Indones J Biomed Sci. 2021;15(2):164.

Qin Z, Wang S, Lin Y, Zhao Y, Yang S, Song J, et al. Antihyperuricemic effect of mangiferin aglycon derivative J99745 by inhibiting xanthine oxidase activity and urate transporter 1 expression in mice. Acta Pharm Sin B [Internet]. 2018;8(2):306–15. Available from:

Oh DR, Kim JR, Choi CY, Choi CH, Na CS, Kang BY, et al. Effects of ChondroT on potassium Oxonate-induced Hyperuricemic mice: Downregulation of xanthine oxidase and urate transporter 1 11 Medical and Health Sciences 1103 Clinical Sciences. BMC Complement Altern Med. 2019;19(1):1–8.

Bell PG, Gaze DC, Davison GW, George TW, Scotter MJ, Howatson G. Montmorency tart cherry (Prunus cerasus L.) concentrate lowers uric acid, independent of plasma cyanidin-3-O-glucosiderutinoside. J Funct Foods [Internet]. 2014;11(C):82–90. Available from: http://dx. 1016/j.jff.2014 .09.004

Baumgartner S, Yeh LT, Shen Z, Kerr B, Manhard K, Quart B. The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout. J Clin Pharmacol. 2018;58(9):1164–70.

Wang MX, Liu YL, Yang Y, Zhang DM, Kong LD. Nuciferine restores potassium oxonate-induced hyperuricemia and kidney inflammation in mice. Eur J Pharmacol [Internet]. 2015;747:59–70. Available from:

Dincer HE, Dincer AP, Levinson DJ. Asymptomatic hyperuricemia: To treat or not to treat. Cleve Clin J Med. 2002;69(8):594–608.

Murugaiyah V, Chan KL. Mechanisms of antihyperuricemic effect of Phyllanthus niruri and its lignan constituents. J Ethnopharmacol. 2009;124(2):233–9.

Yu Z, Wing PF, Cheng CHK. The dual actions of morin (3,5,7,2′,4′-pentahydroxyflavone) as a hypouricemic agent: Uricosuric effect and xanthine oxidase inhibitory activity. J Pharmacol Exp Ther. 2006;316(1):169–75.

Alkhatib B. Annals of Clinical Case Reports The Effect of Selected Traditional Herbal Combination with Royal Jelly on Kidney Function : Case Series. 2021;(September).